Google updates Advertising Policy to address Opioid Painkillers
The update aims to strike a balance between restricting the promotion and sale of these drugs while allowing for public health discussions on this critical issue.
Google yesterday announced an update to its Healthcare and medicines policy specifically regarding prescription opioid painkillers. The update aims to strike a balance between restricting the promotion and sale of these drugs while allowing for public health discussions on this critical issue.
Opioid addiction is a significant public health concern in many countries, including the United States. Prescription opioid painkillers, while effective for managing severe pain, can be highly addictive. According to the Centers for Disease Control and Prevention (CDC), in the United States alone, over 100,000 people died of opioid overdoses in 2021.
Previously, Google Ads strictly prohibited any advertising that promoted or sold prescription opioid painkillers. The updated policy introduces a new certification program for advertisers.
Policy Maintains Prohibition on Sales and Promotion: The core principle remains unchanged – Google Ads will not allow advertisements that directly promote or sell prescription opioid painkillers. This includes medications used for managing pain, such as oxycodone or hydrocodone.
Certification for Public Health Discussions: The new policy allows certified advertisers to mention opioid painkillers within their advertisements and landing pages, provided they do not promote or sell them. This could allow public health organizations, advocacy groups, or government agencies to discuss issues such as:
- Opioid addiction risks and prevention
- Treatment options for opioid use disorder
- Public policy solutions for addressing the opioid crisis
Certification Process: Details on the certification process are limited, but Google provides a link within the policy update for advertisers to apply.
Strict Enforcement: Google emphasizes that it will take a serious approach to potential misuse of this certification program. Any advertiser found to be promoting or selling opioid painkillers despite certification will face account suspension without warning and a permanent ban from Google Ads advertising.
Impact of the Policy Update
The updated policy reflects Google's attempt to balance public health considerations with its advertising regulations. By allowing certified advertisers to discuss opioid painkillers for educational purposes, Google may facilitate more open conversations about this critical public health issue. However, the strict enforcement measures highlight Google's commitment to preventing any exploitation of this program for illegal promotion of these medications.
The effectiveness of this policy update will likely depend on the details of the certification program and its enforcement. Whether it successfully facilitates public health discussions on opioid painkillers while preventing deceptive advertising practices remains to be seen.
Subscribe to our free weekly LinkedIn newsletter for a weekend roundup, or upgrade to our real-time updates for just $10/year. Get the latest marketing news and insights delivered straight to your inbox.